These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 27537991)

  • 1. IL-4 and IL-13 Inhibition in Atopic Dermatitis.
    Matsunaga MC; Yamauchi PS
    J Drugs Dermatol; 2016 Aug; 15(8):925-9. PubMed ID: 27537991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Interleukins 4 and/or 13 in the Pathophysiology and Treatment of Atopic Dermatitis.
    Silverberg JI; Kantor R
    Dermatol Clin; 2017 Jul; 35(3):327-334. PubMed ID: 28577802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asthma and Atopic Dermatitis: A Review of Targeted Inhibition of Interleukin-4 and Interleukin-13 As Therapy for Atopic Disease.
    Buzney CD; Gottlieb AB; Rosmarin D
    J Drugs Dermatol; 2016 Feb; 15(2):165-71. PubMed ID: 26885783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches.
    Moyle M; Cevikbas F; Harden JL; Guttman-Yassky E
    Exp Dermatol; 2019 Jul; 28(7):756-768. PubMed ID: 30825336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dupilumab for Moderate-to-Severe Atopic Dermatitis.
    Vangipuram R; Tyring SK
    Skin Therapy Lett; 2017 Nov; 22(6):1-4. PubMed ID: 29091379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atopic dermatitis: phototherapy and systemic therapy.
    Davis DM; Borok J; Udkoff J; Lio P; Spergel J
    Semin Cutan Med Surg; 2017 Sep; 36(3):118-123. PubMed ID: 28895958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologics for Atopic Dermatitis.
    Boguniewicz M
    Immunol Allergy Clin North Am; 2020 Nov; 40(4):593-607. PubMed ID: 33012322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Therapeutic Approaches and Targets for the Treatment of Atopic Dermatitis.
    Pescitelli L; Rosi E; Ricceri F; Pimpinelli N; Prignano F
    Curr Pharm Biotechnol; 2021; 22(1):73-84. PubMed ID: 32525769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dupilumab in the treatment of moderate-to-severe atopic dermatitis.
    Kraft M; Worm M
    Expert Rev Clin Immunol; 2017 Apr; 13(4):301-310. PubMed ID: 28165826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy.
    D'Erme AM; Romanelli M; Chiricozzi A
    Drug Des Devel Ther; 2017; 11():1473-1480. PubMed ID: 28553077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-13 antagonists in the treatment of atopic dermatitis.
    Tubau C; Puig L
    Immunotherapy; 2021 Mar; 13(4):327-344. PubMed ID: 33430628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug evaluation review: dupilumab in atopic dermatitis.
    Hamilton JD; Ungar B; Guttman-Yassky E
    Immunotherapy; 2015; 7(10):1043-58. PubMed ID: 26598956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-4/IL-13 antagonist DNA vaccination successfully suppresses Th2 type chronic dermatitis.
    Morioka T; Yamanaka K; Mori H; Omoto Y; Tokime K; Kakeda M; Kurokawa I; Gabazza EC; Tsubura A; Yasutomi Y; Mizutani H
    Br J Dermatol; 2009 Jun; 160(6):1172-9. PubMed ID: 19416272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drugmakers cling to dual IL-13/IL-4 blockbuster hopes.
    Sheridan C
    Nat Biotechnol; 2018 Jan; 36(1):3-5. PubMed ID: 29319691
    [No Abstract]   [Full Text] [Related]  

  • 15. An updated reappraisal of dupilumab in children and adolescents with moderate-severe atopic dermatitis.
    Ciprandi G; Licari A; Tosca MA; Miraglia Del Giudice M; Belloni Fortina A; Marseglia GL
    Pediatr Allergy Immunol; 2024 Jun; 35(6):e14181. PubMed ID: 38934228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dupilumab, A Monoclonal Antibody for Atopic Dermatitis: A Review of Current Literature.
    Blakely K; Gooderham M; Papp K
    Skin Therapy Lett; 2016 Mar; 21(2):1-5. PubMed ID: 27223113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic targeting of the IL-13 pathway in skin inflammation.
    Tubau C; Puig L
    Expert Rev Clin Immunol; 2021 Jan; 17(1):15-25. PubMed ID: 33275064
    [No Abstract]   [Full Text] [Related]  

  • 18. Dupilumab for the treatment of adolescents with atopic dermatitis.
    Senner S; Seegräber M; Frey S; Kendziora B; Eicher L; Wollenberg A
    Expert Rev Clin Immunol; 2020 Jul; 16(7):641-650. PubMed ID: 32720530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Clinician's Guide to the Recognition and Management of Dupilumab-Associated Conjunctivitis.
    Agnihotri G; Shi K; Lio PA
    Drugs R D; 2019 Dec; 19(4):311-318. PubMed ID: 31728936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic strategies in extrinsic atopic dermatitis: focus on inhibition of IL-4 as a new pharmacological approach.
    Di Lernia V
    Expert Opin Ther Targets; 2015 Jan; 19(1):87-96. PubMed ID: 25283256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.